This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. SAP's CEO, Christian Klein, speaks at Sapphire. SAP is not just an enterprise software ...
On Monday, the European heavyweight announced its intention to acquire German AI startup Prior Labs for an undisclosed amount. Pending regulatory approval, SAP plans to invest €1 billion ...
The use of aficamten (Myqorzo; Cytokinetics), a selective cardiac myosin inhibitor, in patients with nonobstructive hypertrophic cardiomyopathy (HCM) improves physical limitations, symptoms, and peak ...
Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...
Hypertrophic cardiomyopathy (HCM) is a progressive heart disease with four stages. At each stage, HCM has a greater impact on the heart’s structure and function. In the earliest stage, a person will ...
Rohith Reddy, consultant behind HCM rollouts at Charter Communications and Dr. Reddy’s Labs, publishes comprehensive implementation guide for enterprise leaders Most implementations don’t fail because ...
Abstract: Enterprise Resource Planning (ERP) systems have revolutionised how organisations integrate and manage their operations by providing a unified platform for various business functions. While ...
Arrhythmias, or irregular heart rhythms, are common complications of HCM. The thickened heart muscle disrupts the electrical pathways that coordinate heartbeat, leading to arrhythmias. Atrial ...
MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...
Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain. We conducted a phase 3, ...
MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...
Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results